FDA issues Safety Alert for clarithromycin
Editor's Note
The Food and Drug Administration (FDA) on February 22 issued a Safety Alert for clarithromycin (Biaxin) because of the potential increased risk of heart problems or death associated with this antibiotic in patients with heart disease.
A large clinical trial with 10-year follow-up found an unexpected increase in deaths among coronary heart disease patients 1 year or longer after receiving a 2-week course of clarithromycin.
As a result, the FDA is advising prescribers to consider using other antibiotics in such patients and has added the study results to the drug label.
Posted 02/22/2018] AUDIENCE: Health Professional, Internal Medicine, Cardiology, Patient ISSUE: FDA is advising caution before prescribing the antibiotic clarithromycin (Biaxin) to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later.
Free Daily News
- Hospital addresses barriers to patient rest, recovery
- Study: Psilocybin therapy reduces depression in frontline clinicians
- Exclusive articles preview OR Business Management Conference sessions
- Study: Surgeries improve survival in young BRCA-positive breast cancer patients
- Study: Advanced recovery room care could reduce long-term postoperative mortality
- FDA designates Class 1 recalls for balloon catheters, radiographic markers
- Orthopedic surgery in 2025: Embracing innovation, preserving autonomy
- Medtronic, Zimmer Biomet challenge Intuitive Surgical’s robotic surgery dominance
- Anthem’s anesthesia time limit policy, reversal sparks new legislation
- Simple procedure or ‘surgery’? Questionable medical billing practices cause confusion